Thrombosis in leukemia: incidence, causes, and practical management

Area of Science:

• Hematology
• Oncology
• Thrombosis Research

Background:

• Coagulation disorders are a significant clinical issue in acute leukemia (AL), presenting as thrombotic or hemorrhagic events.
• The reported incidence of these events in AL patients varies widely (1-36%), influenced by patient characteristics, study design, and treatment protocols.
• The complex pathophysiology involves multiple factors contributing to a cancer procoagulant state, including blast synthesis of procoagulant factors and chemotherapy agents like L-asparaginase.

Purpose of the Study:

• To review the incidence, pathophysiology, and current treatment strategies for coagulation disorders in acute leukemia.
• To highlight the need for further investigation into optimal management of thrombosis in AL patients.

Main Methods:

• Literature review and synthesis of existing data on coagulation disorders in acute leukemia.
• Analysis of factors contributing to the procoagulant state in AL.
• Evaluation of current treatment modalities and their limitations.

Main Results:

• Coagulation disorders are common in AL, with variable reported incidence.
• Multiple factors contribute to thrombosis risk in AL, including cancer-specific elements and medical interventions.
• Current treatment primarily involves heparin followed by vitamin K antagonists for 3-6 months.

Conclusions:

• Coagulation disorders are a complex challenge in acute leukemia management.
• Randomized controlled trials are essential to establish definitive safety, duration, and efficacy of anticoagulant therapies in AL patients with thrombosis.